ArticleFrontiers in immunology2026
Immunometabolic reprogramming and glycolysis-associated signatures in sepsis: insights from single-cell RNA sequencing and machine learning.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunometabolic remodeling is central to sepsis, yet robust glycolysis-associated biomarkers and their cell-type context remain unclear. Methods: We integrated peripheral blood scRNA-seq (GSE175453) and a whole-blood microarray cohort (GSE100159). Glycolysis activity was scored by AUCell (HALLMARK_GLYCOLYSIS), hub genes were prioritized by LASSO/random forest/Boruta, communication was inferred by ligand-receptor analysis, and qRT-PCR was performed in CLP vs control mice. Results: Sepsis showed myeloid predominance and increased glycolysis scores, most evident in monocytes and plasma cells. Five candidates (GLRX, MDH1, MDH2, TGFBI, COPB2) displayed good discriminatory performance in bulk data; TGFBI was monocyte-enriched and centrally positioned in a dense communication network with B cells/plasma cells/neutrophils. qRT-PCR confirmed a significant between-group difference for TGFBI in the CLP model. Conclusions: These findings link enhanced glycolysis-associated programs to a monocyte-centered TGFBI communication pattern and prioritize TGFBI as a candidate biomarker for further validation in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.